News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,288 Results
Type
Article (42579)
Company Profile (282)
Press Release (657427)
Section
Business (207867)
Career Advice (2594)
Deals (35833)
Drug Delivery (111)
Drug Development (83156)
Employer Resources (176)
FDA (16385)
Job Trends (15135)
News (351864)
Policy (33123)
Tag
Academia (2645)
Alliances (49849)
Alzheimer's disease (1264)
Approvals (16310)
Artificial intelligence (147)
Bankruptcy (359)
Best Places to Work (11775)
Biotechnology (203)
Breast cancer (129)
Cancer (1141)
Cardiovascular disease (109)
Career advice (2167)
Cell therapy (251)
Clinical research (65989)
Collaboration (400)
Compensation (202)
COVID-19 (2634)
C-suite (102)
Data (1146)
Diabetes (155)
Diagnostics (6254)
Drug pricing (93)
Earnings (85168)
Employer resources (154)
Events (110997)
Executive appointments (332)
FDA (16948)
Funding (369)
Gene therapy (193)
GLP-1 (645)
Government (4485)
Healthcare (19217)
Infectious disease (2723)
Inflammatory bowel disease (117)
Interviews (455)
IPO (16440)
Job creations (3722)
Job search strategy (1818)
Layoffs (441)
Legal (7980)
Lung cancer (180)
Manufacturing (190)
Medical device (13501)
Medtech (13506)
Mergers & acquisitions (19473)
Metabolic disorders (445)
Neuroscience (1559)
NextGen Class of 2024 (6790)
Non-profit (4673)
Northern California (1499)
Obesity (257)
Opinion (223)
Patents (108)
People (58680)
Phase I (20998)
Phase II (28958)
Phase III (21474)
Pipeline (467)
Postmarket research (2577)
Preclinical (8651)
Radiopharmaceuticals (244)
Rare diseases (236)
Real estate (6001)
Regulatory (21983)
Research institute (2409)
Resumes & cover letters (442)
Southern California (1317)
Startups (3670)
United States (13772)
Vaccines (589)
Weight loss (204)
Date
Today (148)
Last 7 days (668)
Last 30 days (3614)
Last 365 days (36553)
2024 (33566)
2023 (40825)
2022 (51837)
2021 (56462)
2020 (54989)
2019 (47830)
2018 (36229)
2017 (33066)
2016 (32470)
2015 (38379)
2014 (32020)
2013 (27103)
2012 (29296)
2011 (29955)
2010 (27867)
Location
Africa (814)
Arizona (195)
Asia (38330)
Australia (6384)
California (3379)
Canada (1300)
China (264)
Colorado (150)
Connecticut (156)
Europe (83640)
Florida (468)
Georgia (121)
Illinois (371)
Indiana (199)
Kansas (97)
Maryland (592)
Massachusetts (2651)
Michigan (158)
Minnesota (280)
New Jersey (969)
New York (977)
North Carolina (742)
Northern California (1499)
Ohio (139)
Pennsylvania (853)
South America (1189)
Southern California (1317)
Texas (481)
Washington State (364)
700,288 Results for "i peace inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
Heartseed Inc., a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc., a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed’s proprietary cardiomyocytes differentiation and purification methods.
November 1, 2023
·
3 min read
Business
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.First Commercial Agreement for DispersinB®
Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.
June 25, 2024
·
3 min read
Policy
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.
June 20, 2024
·
2 min read
Drug Development
Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab
On the heels of Keytruda’s success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.
October 8, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927
November 5, 2024
·
1 min read
Pharm Country
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.
June 27, 2024
·
2 min read
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PRNewswire -- I Peace, Inc. announced that the company has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing
November 1, 2022
·
3 min read
I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”
I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette.
December 22, 2022
·
2 min read
Drug Development
Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV
Avirmax Biopharma, Inc. is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration.
May 30, 2024
·
2 min read
Press Releases
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
November 22, 2024
·
7 min read
1 of 70,029
Next